Our Blog & Resources
Unlock a goldmine of cutting-edge knowledge and resources on our blog, where we delve into the forefront of precision medicine, offering expert perspectives, actionable insights, and game-changing discoveries to empower your journey in shaping the future of healthcare.
Advanced filters :
March: 42-year-old male with a metastatic colorectal cancer
We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.
Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory. Gosselies, Belgium and Paris, France,...
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services
In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...
February: 40-year-old male with a stage IV glioma cancer
We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...
Advancing personalized cancer treatment: Webinar Replay
Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer
Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...
Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar
Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine
Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...
January: 45-year-old male with an intrahepatic cholangiocarcinoma
We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers
Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...
OncoDNA laboratory has received the CAP accreditation
Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...
December: 52-year-old male with a stage IV gastric cancer
Case description: Gastric cancer is one of the leading causes of cancer-related mortality worldwide, with a 5-year survival rate ranging from 5% to 20% for advanced-stage cases (PMID: 30853093). We describe the case of a...
Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer
Overview: The pivotal role of early detection of cancer recurrence and the precise monitoring of minimal residual disease (MRD) after surgery cannot be overstated, especially in the context of non-small cell lung cancer (NSCLC) where...
OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, Germany
OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment, today has announced the implementation of OncoDEEP® Kit in clinical routine by the Institute of Pathology at the Klinikum Region Hannover...
OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancer
OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today has announced its support to the extension of the AURORA program, which aims to...
Join us in this video as Marcel Trautmann, Head of Molecular Diagnostics within the first German Department of Pathology and member of the German Network for Personalized Medicine (DNPM), shares his firsthand experience with OncoDEEP®...
November: 68 year-old man with a Stage IV Prostate cancer
Case description: Prostate cancer is the fifth leading cause of cancer death in the world. When the cancer is localized, it is usually indolent, with a 5-year survival rate of nearly 100%. However, when the...
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across...
ctDNA’s promise in early detection of MRD and recurrence prediction for Head and Neck Squamous Cell Carcinoma
Two recent studies, led by the Institute Curie in collaboration with OncoDNA, have assessed the potential of circulating tumor DNA (ctDNA) as a biomarker for early detection of Molecular Residual Disease (MRD) and predicting recurrence...
October: 65 year-old woman with a Metastatic Breast Cancer with hormone receptor (HR)-positive
Case description: A 65 year-old woman was diagnosed with a metastatic breast cancer, hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Thanks to our OncoDEEP analysis, we notably detected a variant PIK3CA...
OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house
OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house. Gosselies, Belgium, October 20th, 2023 – OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment,...
Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Comprehensive genomic profiling (CGP) and reliable molecular characterization of solid tumors using NGS technology has become a key tool to facilitate biomarker-matched therapy selection. With a broad spectrum of therapies already approved or in clinical...
C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe
OncoDNA’s lab in France is the first in the EU to enable access to the C2inform test for clinical decision-making Gosselies — (October 19, 2023) — OncoDNA, a genomic and theranostic company specializing in precision...
Scientific Review: Latest Discoveries in Oncology
In a rapidly evolving medical landscape, staying updated with the latest breakthroughs is crucial. Our team of experts constantly monitors the field to bring you the most relevant and groundbreaking news. This month, we’ve handpicked...
Enhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies
What is HRD Genomic Scar? The HRD Genomic Scar (GS) is essentially a collection of genetic changes or signatures that indicate a cell’s inability to repair DNA damage effectively using this specific DNA repair pathway....
September: 53 year-old man with Metastatic Colorectal Cancer
Case description: A 53 year-old man was diagnosed with metastatic colorectal cancer. In 2023, the primary sample was tested using our OncoDEEP® Kit. The analysis revealed a FMN1-NTRK3 gene fusion for this patient and a...
Dive Deep into OncoDNA’s journey tells by its founder Jean-Pol Detiffe ! In this video interview, you’ll discover the inspiration behind OncoDNA’s tests and its pioneering decentralized solution: OncoDEEP Kit. But that’s not all!...
July: 53 year-old man with Non-Small Cell Lung Cancer
Case description: A 53 year-old man was diagnosed with a metastatic Non-Small Cell Lung Cancer (mNSCLC) in 2021. This patient was a non-smoker. In 2022, a biopsy from a bone metastasis was tested using our...
Cancer Management: Breast Cancer
What is Breast Cancer? With an estimated 2.26 million new cancer cases and 685 000 deaths in women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in 2020,...
Revolutionizing precision medicine: OncoDNA’s data innovation story
Once upon a time, in a world where personalized medicine was a luxury reserved for the few, a small but passionate group embarked on an audacious journey to change precision medicine. It was a crazy...
OncoDNA announces the closing of a round C financing of 6,5 M€
OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 M€, entirely subscribed by...
Revolutionizing laboratory operations with OncoDEEP® Kit
Biomarker testing is critical to learning more about each patient’s tumor type and can be used to help determine treatment options. Based on the test results, patients may be matched with targeted therapies aimed at...